{"organizations": [], "uuid": "488d324ce84211afcecad98ce6a87988a2f7d87e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-jj-posts-q1-adj-non-gaap-eps-206/brief-jj-posts-q1-adj-non-gaap-eps-2-06-idUSASC09W2N", "country": "US", "domain_rank": 408, "title": "BRIEF-J&J Posts Q1 Adj Non-Gaap EPS $2.06", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T14:06:00.000+03:00", "replies_count": 0, "uuid": "488d324ce84211afcecad98ce6a87988a2f7d87e"}, "author": "", "url": "https://www.reuters.com/article/brief-jj-posts-q1-adj-non-gaap-eps-206/brief-jj-posts-q1-adj-non-gaap-eps-2-06-idUSASC09W2N", "ord_in_thread": 0, "title": "BRIEF-J&J Posts Q1 Adj Non-Gaap EPS $2.06", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "johnson & johnson", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 11:08 AM / Updated 6 minutes ago BRIEF-J&J Posts Q1 Adj Non-Gaap EPS $2.06 Reuters Staff \nApril 17 (Reuters) - Johnson & Johnson: \n* REPORTS 2018 FIRST-QUARTER RESULTS * Q1 SALES $20 BILLION VERSUS I/B/E/S VIEW $19.46 BILLION \n* Q1 EARNINGS PER SHARE VIEW $2.02 — THOMSON REUTERS I/B/E/S \n* REAFFIRMS FY 2018 ADJUSTED EARNINGS PER SHARE VIEW $8.00 TO $8.20 \n* Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $2.06 EXCLUDING ITEMS * SEES FY 2018 SALES $81 BILLION TO $81.8 BILLION \n* PLANS TO IMPLEMENT ACTIONS ACROSS ITS GLOBAL SUPPLY CHAIN \n* EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON AN OPERATIONAL BASIS, WORLDWIDE SALES INCREASED 4.3 PCT IN QUARTER \n* EXPECTS TO RECORD PRE-TAX RESTRUCTURING CHARGES OF APPROXIMATELY $1.9 TO $2.3 BILLION, WHICH WILL BE TREATED AS A SPECIAL ITEM \n* QTRLY WORLDWIDE CONSUMER SALES $3,398 MILLION VERSUS $3,228 MILLION REPORTED LAST YEAR \n* EXPECTS ACTIONS TO GENERATE APPROXIMATELY $0.6 TO $0.8 BILLION IN ANNUAL PRE-TAX COST SAVINGS THAT WILL BE SUBSTANTIALLY DELIVERED BY 2022 \n* QTRLY WORLDWIDE PHARMACEUTICAL SALES $9,844 MILLION VERSUS $8,245 MILLION REPORTED LAST YEAR \n* EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON AN OPERATIONAL BASIS, QTRLY DOMESTIC SALES INCREASED 1.3 PCT \n* QTRLY WORLDWIDE MEDICAL DEVICES SALES $6,767 MILLION VERSUS $6,293 MILLION REPORTED LAST YEAR \n* J&J QTRLY WORLDWIDE REMICADE SALES $1,389 MILLION VERSUS $1,672 MILLION REPORTED LAST YEAR \n* EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON AN OPERATIONAL BASIS, QTRLY INTERNATIONAL SALES INCREASED 7.6 PCT \n* J&J QTRLY WORLDWIDE INVOKANA/INVOKAMET SALES $248 MILLION VERSUS $284 MILLION REPORTED LAST YEAR \n* EXPECTS SUPPLY CHAIN ACTIONS WILL INCLUDE EXPANDING USE OF STRATEGIC COLLABORATIONS \n* FIRST-QUARTER 2018 NET EARNINGS INCLUDED AFTER-TAX INTANGIBLE AMORTIZATION EXPENSE OF APPROXIMATELY $1.0 BILLION \n* FIRST-QUARTER NET EARNINGS ALSO INCLUDED CHARGE FOR AFTER-TAX SPECIAL ITEMS OF APPROXIMATELY $0.3 BILLION \n* QTRLY WORLDWIDE VELCADE SALES $313 MILLION VERSUS $280 MILLION REPORTED LAST YEAR \n* QTRLY WORLDWIDE ZYTIGA SALES $845 MILLION VERSUS $523 MILLION REPORTED LAST YEAR \n* U.S. TAX LEGISLATION PASSED LAST YEAR IS CREATING OPPORTUNITY TO INVEST MORE THAN $30 BILLION IN RESEARCH AND DEVELOPMENT, CAPITAL INVESTMENTS IN U.S. OVER NEXT 4 YRS \n* IN MEDICAL DEVICES BUSINESSES, “HAVE AREAS OF LEADERSHIP AND CONTINUE TO MAKE INVESTMENTS AND PORTFOLIO CHOICES TO IMPROVE PERFORMANCE” \n* FY2018 EARNINGS PER SHARE VIEW $8.10, REVENUE VIEW $81.13 BILLION — THOMSON REUTERS I/B/E/S \n* DISCUSSIONS REGARDING SPECIFIC FUTURE ACTIONS IN GLOBAL SUPPLY CHAIN ARE ONGOING Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-17T14:06:00.000+03:00", "crawled": "2018-04-17T14:20:05.038+03:00", "highlightTitle": ""}